Anti-RBD-4 antibody (Casirivimab)

Reference: PTXCOV-A552



Product type


Description of Anti-RBD-4 antibody (Casirivimab)

General information on Anti-RBD-4 antibody

The receptor binding domain (RBD) of the SARS-CoV-2 spike protein is the most important target for the design of novel therapies for COVID-19. The development of antibodies that can target this specific area can be done in vivo, which is a time-consuming in vitro process or which can take advantage of the flexibility of visualization technologies such as pH age visualization. Anti-CoV-RBD antibody was developed by pHa to visualize the extensive library of COVID-19 (LiAb-SFCOVID-19 ™) antibodies against SARS-CoV-2 RBD. Whereas generation of antibodies based on pH age does not require animal immunization or the use of immunogenic antigens, only small RBD proteins are used to isolate specific RBD ligands from the LiAb-SFCOVID-19 TM library. Furthermore, since the library is composed of immune libraries from COVID-19 patients, it possesses the largest and most important biological antibodies with important neutralizing activities.
Therefore, this specific antibody is a fully human immunoglobulin in IgG format. The ELISA (Enzyme-linked immunosorbent assay) test was used to test and verify its affinity for recombinantly expressed RBD. In addition, the neutralizing activity was tested by the SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT), which is designed to rapidly assess the neutralization potential of new antibodies without using natural viral particles.
Finally, IgG antibodies are expressed in the XtenCHO ™ high throughput mammalian transient system, exhibit very stable stability and consistently produce high yields.

Product nameAnti-RBD-4 antibody (Casirivimab)
Expression systemMammalian
Molecular weight150kDa
BufferPBS, pH7,5
Delivery conditionDry ice
Storage condition4°C for short term; -20°c or -80°C for long term
Aliases /SynonymsREGN10933
Related ProductsRBD Domain,SARS-CoV-2 RBD of Spike protein, N501Y – B 1.1.7 lineage – UK Alpha Variant,RBD Domain,SARS-CoV-2 RBD of Spike protein, N501Y – B 1.1.7 lineage – UK Alpha Variant,SARS-CoV-2 RBD of Spike protein, K417N, E484K, N501Y – B.1.351 lineage – SA Beta Variant,SARS-CoV-2 RBD of Spike protein, E484K
NoteFor research use only. Not suitable for in vitro diagnostic and human use.
ClonalityMonoclonal Antibody


There are no reviews yet.

Be the first to review “Anti-RBD-4 antibody (Casirivimab)”

Your email address will not be published.



Please select the country of delivery so that we can send you the quotation including shipping costs.

Thank you for your request! You will receive your quotation per e-mail in a few seconds.

If you did not receive your quotation, please check your spam folder.

Contact us to order

+33 (0)3 90 20 54 70

Write us